PGS Publication: PGP000149

Publication Information (EuropePMC)
Title Polygenic hazard score is associated with prostate cancer in multi-ethnic populations.
PubMed ID 33623038(Europe PMC)
doi 10.1038/s41467-021-21287-0
Publication Date Feb. 23, 2021
Journal Nat Commun
Author(s) Huynh-Le MP, Fan CC, Karunamuni R, Thompson WK, Martinez ME, Eeles RA, Kote-Jarai Z, Muir K, Schleutker J, Pashayan N, Batra J, Grönberg H, Neal DE, Donovan JL, Hamdy FC, Martin RM, Nielsen SF, Nordestgaard BG, Wiklund F, Tangen CM, Giles GG, Wolk A, Albanes D, Travis RC, Blot WJ, Zheng W, Sanderson M, Stanford JL, Mucci LA, West CML, Kibel AS, Cussenot O, Berndt SI, Koutros S, Sørensen KD, Cybulski C, Grindedal EM, Menegaux F, Khaw KT, Park JY, Ingles SA, Maier C, Hamilton RJ, Thibodeau SN, Rosenstein BS, Lu YJ, Watya S, Vega A, Kogevinas M, Penney KL, Huff C, Teixeira MR, Multigner L, Leach RJ, Cannon-Albright L, Brenner H, John EM, Kaneva R, Logothetis CJ, Neuhausen SL, De Ruyck K, Pandha H, Razack A, Newcomb LF, Fowke JH, Gamulin M, Usmani N, Claessens F, Gago-Dominguez M, Townsend PA, Bush WS, Roobol MJ, Parent MÉ, Hu JJ, Mills IG, Andreassen OA, Dale AM, Seibert TM, UKGPCS collaborators, APCB (Australian Prostate Cancer BioResource), NC-LA PCaP Investigators, IMPACT Study Steering Committee and Collaborators, Canary PASS Investigators, Profile Study Steering Committee, PRACTICAL Consortium.
Released in PGS Catalog: March 22, 2021

Associated Polygenic Score(s)

Filter PGS by Participant Ancestry
Individuals included in:
G - Source of Variant Associations (GWAS)
D - Score Development/Training
E - PGS Evaluation
List of ancestries includes:
Display options:
Ancestry legend
Multi-ancestry (including European)
Multi-ancestry (excluding European)
African
East Asian
South Asian
Additional Asian Ancestries
European
Greater Middle Eastern
Hispanic or Latin American
Additional Diverse Ancestries
Not Reported

PGS Developed By This Publication

Polygenic Score ID & Name PGS Publication ID (PGP) Reported Trait Mapped Trait(s) (Ontology) Number of Variants Ancestry distribution
GWAS
Dev
Eval
 Scoring File (FTP Link)
PGS000741
(PCa_PHS2)
 PGP000149 |
Huynh-Le MP et al. Nat Commun (2021)
 Prostate cancer prostate carcinoma 46
-
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000741/ScoringFiles/PGS000741.txt.gz

Performance Metrics

Disclaimer: The performance metrics are displayed as reported by the source studies. It is important to note that metrics are not necessarily comparable with each other. For example, metrics depend on the sample characteristics (described by the PGS Catalog Sample Set [PSS] ID), phenotyping, and statistical modelling. Please refer to the source publication for additional guidance on performance.

PGS Performance
Metric ID (PPM) 		Evaluated Score PGS Sample Set ID
(PSS) 		Performance Source Trait PGS Effect Sizes
(per SD change) 		Classification Metrics Other Metrics Covariates Included in the Model PGS Performance:
Other Relevant Information
PPM001790 PGS000741
(PCa_PHS2)
 PSS000925|
Multi-ancestry (excluding European)|
80,491 individuals
 PGP000149 |
Huynh-Le MP et al. Nat Commun (2021)
 Reported Trait: Prostate cancer (age at diagnosis) — — Hazard ratio (HR, top 20% vs. bottom 20%): 5.32 [4.99, 5.7] — —
PPM001791 PGS000741
(PCa_PHS2)
 PSS000924|
Multi-ancestry (including European)|
71,856 individuals
 PGP000149 |
Huynh-Le MP et al. Nat Commun (2021)
 Reported Trait: Prostate cancer (age at diagnosis) — — Hazard ratio (HR, top 20% vs. bottom 20%): 5.54 [5.18, 5.93] — —
PPM001792 PGS000741
(PCa_PHS2)
 PSS000923|
Multi-ancestry (excluding European)|
2,382 individuals
 PGP000149 |
Huynh-Le MP et al. Nat Commun (2021)
 Reported Trait: Prostate cancer (age at diagnosis) — — Hazard ratio (HR, top 20% vs. bottom 20%): 4.49 [3.23, 6.33] — —
PPM001793 PGS000741
(PCa_PHS2)
 PSS000922|
Multi-ancestry (excluding European)|
6,253 individuals
 PGP000149 |
Huynh-Le MP et al. Nat Commun (2021)
 Reported Trait: Prostate cancer (age at diagnosis) — — Hazard ratio (HR, top 20% vs. bottom 20%): 2.54 [2.08, 3.1] — —
PPM001797 PGS000741
(PCa_PHS2)
 PSS000922|
Multi-ancestry (excluding European)|
6,253 individuals
 PGP000149 |
Huynh-Le MP et al. Nat Commun (2021)
 Reported Trait: Aggressive prostate cancer (age at diagnosis) — — Hazard ratio (HR, top 20% vs. bottom 20%): 2.43 [1.51, 4.05] — —
PPM001798 PGS000741
(PCa_PHS2)
 PSS000925|
Multi-ancestry (excluding European)|
80,491 individuals
 PGP000149 |
Huynh-Le MP et al. Nat Commun (2021)
 Reported Trait: Prostate cancer mortality (age at death) — — Hazard ratio (HR, top 20% vs. bottom 20%): 5.68 [5.07, 6.46] — —
PPM001800 PGS000741
(PCa_PHS2)
 PSS000924|
Multi-ancestry (including European)|
71,856 individuals
 PGP000149 |
Huynh-Le MP et al. Nat Commun (2021)
 Reported Trait: Prostate cancer in men with a family history of prostate cancer β: 2.06 — Hazard ratio (HR, top 20% vs. bottom 20%): 4.8 — —
PPM001795 PGS000741
(PCa_PHS2)
 PSS000924|
Multi-ancestry (including European)|
71,856 individuals
 PGP000149 |
Huynh-Le MP et al. Nat Commun (2021)
 Reported Trait: Aggressive prostate cancer (age at diagnosis) — — Hazard ratio (HR, top 20% vs. bottom 20%): 5.62 [5.25, 6.05] — —
PPM001803 PGS000741
(PCa_PHS2)
 PSS000925|
Multi-ancestry (excluding European)|
80,491 individuals
 PGP000149 |
Huynh-Le MP et al. Nat Commun (2021)
 Reported Trait: Aggressive prostate cancer in men with a family history of prostate cancer β: 2.16 — Hazard ratio (HR, top 20% vs. bottom 20%): 5.12 — —
PPM001804 PGS000741
(PCa_PHS2)
 PSS000924|
Multi-ancestry (including European)|
71,856 individuals
 PGP000149 |
Huynh-Le MP et al. Nat Commun (2021)
 Reported Trait: Aggressive prostate cancer in men with a family history of prostate cancer β: 2.1 — Hazard ratio (HR, top 20% vs. bottom 20%): 4.93 — —
PPM001805 PGS000741
(PCa_PHS2)
 PSS000923|
Multi-ancestry (excluding European)|
2,382 individuals
 PGP000149 |
Huynh-Le MP et al. Nat Commun (2021)
 Reported Trait: Aggressive prostate cancer in men with a family history of prostate cancer β: 1.73 — Hazard ratio (HR, top 20% vs. bottom 20%): 3.6 — —
PPM001806 PGS000741
(PCa_PHS2)
 PSS000922|
Multi-ancestry (excluding European)|
6,253 individuals
 PGP000149 |
Huynh-Le MP et al. Nat Commun (2021)
 Reported Trait: Aggressive prostate cancer in men with a family history of prostate cancer β: 1.1 — Hazard ratio (HR, top 20% vs. bottom 20%): 2.16 — —
PPM001807 PGS000741
(PCa_PHS2)
 PSS000925|
Multi-ancestry (excluding European)|
80,491 individuals
 PGP000149 |
Huynh-Le MP et al. Nat Commun (2021)
 Reported Trait: Prostate cancer mortality in men with a family history of prostate cancer β: 2.2 — Hazard ratio (HR, top 20% vs. bottom 20%): 5.29 — —
PPM001794 PGS000741
(PCa_PHS2)
 PSS000925|
Multi-ancestry (excluding European)|
80,491 individuals
 PGP000149 |
Huynh-Le MP et al. Nat Commun (2021)
 Reported Trait: Aggressive prostate cancer (age at diagnosis) — — Hazard ratio (HR, top 20% vs. bottom 20%): 5.88 [5.48, 6.34] — —
PPM001796 PGS000741
(PCa_PHS2)
 PSS000923|
Multi-ancestry (excluding European)|
2,382 individuals
 PGP000149 |
Huynh-Le MP et al. Nat Commun (2021)
 Reported Trait: Aggressive prostate cancer (age at diagnosis) — — Hazard ratio (HR, top 20% vs. bottom 20%): 5.16 [3.45, 7.78] — —
PPM001799 PGS000741
(PCa_PHS2)
 PSS000925|
Multi-ancestry (excluding European)|
80,491 individuals
 PGP000149 |
Huynh-Le MP et al. Nat Commun (2021)
 Reported Trait: Prostate cancer in men with a family history of prostate cancer β: 1.98 — Hazard ratio (HR, top 20% vs. bottom 20%): 4.48 — —
PPM001801 PGS000741
(PCa_PHS2)
 PSS000923|
Multi-ancestry (excluding European)|
2,382 individuals
 PGP000149 |
Huynh-Le MP et al. Nat Commun (2021)
 Reported Trait: Prostate cancer in men with a family history of prostate cancer β: 1.89 — Hazard ratio (HR, top 20% vs. bottom 20%): 4.17 — —
PPM001802 PGS000741
(PCa_PHS2)
 PSS000922|
Multi-ancestry (excluding European)|
6,253 individuals
 PGP000149 |
Huynh-Le MP et al. Nat Commun (2021)
 Reported Trait: Prostate cancer in men with a family history of prostate cancer β: 1.11 — Hazard ratio (HR, top 20% vs. bottom 20%): 2.22 — —

Evaluated Samples

PGS Sample Set ID
(PSS) 		Phenotype Definitions and Methods Participant Follow-up Time Sample Numbers Age of Study Participants Sample Ancestry Additional Ancestry Description Cohort(s) Additional Sample/Cohort Information
PSS000922 Cases numbers refer to 'any prostate cancer'. Of those, 1424 had aggressive prostate cancer (Gleason score ≥7, PSA ≥ 10 ng/mL, T3–T4 stage, nodal metastases, or distant metastases) and 18 had fatal prostate cancer. Death was determined by the investigators of each contributing study using cancer registries and/or medical records. Age shows the age of diagnosis. 5557 individuals had a family history of prostate cancer (≥1 first degree relative affected). —
[
  • 3,240 cases
  • , 3,013 controls
]
,
100.0 % Male samples
 Mean = 62.0 years
IQR = [56.0, 68.0] years		 African unspecified, NR — 60 cohorts
  • AHS
  • ,ATBC
  • ,Aarhus
  • ,BioVU
  • ,CCI
  • ,CHIPGECS
  • ,COH
  • ,CONOR
  • ,COSM
  • ,CPCS
  • ,CPDR
  • ,CeRePP
  • ,EPIC
  • ,EPICAP
  • ,ERSPC
  • ,ESTHER
  • ,FHCRC
  • ,Gene-PARE
  • ,HPFS
  • ,IMPACT
  • ,IPO-Porto
  • ,KARUPROSTATE
  • ,KULEUVEN
  • ,LAAPC
  • ,MCC-Spain
  • ,MCCS
  • ,MDACCS
  • ,MEC
  • ,MOFFITT
  • ,NMHS
  • ,PASS
  • ,PCMUS
  • ,PCPT
  • ,PCaP
  • ,PHS
  • ,PLCO
  • ,PRAGGA
  • ,PROCAP
  • ,PROFILE
  • ,PROGReSS_PrCa
  • ,PROtEuS
  • ,ProMPT
  • ,ProtecT
  • ,QLD
  • ,RAPPER
  • ,SABOR
  • ,SCCS
  • ,SCPCS
  • ,SEARCH
  • ,SELECT
  • ,SFPCS
  • ,SNP_Prostate_Ghent
  • ,SPAG
  • ,STHM
  • ,TAMPERE
  • ,Toronto
  • ,UKGPCS
  • ,ULM
  • ,WFPCS
  • ,WUGS
 —
PSS000923 Cases numbers refer to 'any prostate cancer'. Of those, 716 had aggressive prostate cancer (Gleason score ≥7, PSA ≥ 10 ng/mL, T3–T4 stage, nodal metastases, or distant metastases) and 57 had fatal prostate cancer. Death was determined by the investigators of each contributing study using cancer registries and/or medical records. Age shows the age of diagnosis. 1028 individuals had a family history of prostate cancer (≥1 first degree relative affected). —
[
  • 1,197 cases
  • , 1,185 controls
]
,
100.0 % Male samples
 Mean = 68.0 years
IQR = [62.0, 74.0] years		 Asian unspecified, NR — 60 cohorts
  • AHS
  • ,ATBC
  • ,Aarhus
  • ,BioVU
  • ,CCI
  • ,CHIPGECS
  • ,COH
  • ,CONOR
  • ,COSM
  • ,CPCS
  • ,CPDR
  • ,CeRePP
  • ,EPIC
  • ,EPICAP
  • ,ERSPC
  • ,ESTHER
  • ,FHCRC
  • ,Gene-PARE
  • ,HPFS
  • ,IMPACT
  • ,IPO-Porto
  • ,KARUPROSTATE
  • ,KULEUVEN
  • ,LAAPC
  • ,MCC-Spain
  • ,MCCS
  • ,MDACCS
  • ,MEC
  • ,MOFFITT
  • ,NMHS
  • ,PASS
  • ,PCMUS
  • ,PCPT
  • ,PCaP
  • ,PHS
  • ,PLCO
  • ,PRAGGA
  • ,PROCAP
  • ,PROFILE
  • ,PROGReSS_PrCa
  • ,PROtEuS
  • ,ProMPT
  • ,ProtecT
  • ,QLD
  • ,RAPPER
  • ,SABOR
  • ,SCCS
  • ,SCPCS
  • ,SEARCH
  • ,SELECT
  • ,SFPCS
  • ,SNP_Prostate_Ghent
  • ,SPAG
  • ,STHM
  • ,TAMPERE
  • ,Toronto
  • ,UKGPCS
  • ,ULM
  • ,WFPCS
  • ,WUGS
 —
PSS000924 Cases numbers refer to 'any prostate cancer'. Of those, 24279 had aggressive prostate cancer (Gleason score ≥7, PSA ≥ 10 ng/mL, T3–T4 stage, nodal metastases, or distant metastases) and 3908 had fatal prostate cancer. Death was determined by the investigators of each contributing study using cancer registries and/or medical records. Age shows the age of diagnosis. 39,445 individuals had a family history of prostate cancer (≥1 first degree relative affected). —
[
  • 45,479 cases
  • , 26,377 controls
]
,
100.0 % Male samples
 Mean = 66.0 years
IQR = [60.0, 71.0] years		 European, NR — 60 cohorts
  • AHS
  • ,ATBC
  • ,Aarhus
  • ,BioVU
  • ,CCI
  • ,CHIPGECS
  • ,COH
  • ,CONOR
  • ,COSM
  • ,CPCS
  • ,CPDR
  • ,CeRePP
  • ,EPIC
  • ,EPICAP
  • ,ERSPC
  • ,ESTHER
  • ,FHCRC
  • ,Gene-PARE
  • ,HPFS
  • ,IMPACT
  • ,IPO-Porto
  • ,KARUPROSTATE
  • ,KULEUVEN
  • ,LAAPC
  • ,MCC-Spain
  • ,MCCS
  • ,MDACCS
  • ,MEC
  • ,MOFFITT
  • ,NMHS
  • ,PASS
  • ,PCMUS
  • ,PCPT
  • ,PCaP
  • ,PHS
  • ,PLCO
  • ,PRAGGA
  • ,PROCAP
  • ,PROFILE
  • ,PROGReSS_PrCa
  • ,PROtEuS
  • ,ProMPT
  • ,ProtecT
  • ,QLD
  • ,RAPPER
  • ,SABOR
  • ,SCCS
  • ,SCPCS
  • ,SEARCH
  • ,SELECT
  • ,SFPCS
  • ,SNP_Prostate_Ghent
  • ,SPAG
  • ,STHM
  • ,TAMPERE
  • ,Toronto
  • ,UKGPCS
  • ,ULM
  • ,WFPCS
  • ,WUGS
 —
PSS000925 Cases numbers refer to 'any prostate cancer'. Of those, 24279 had aggressive prostate cancer (Gleason score ≥7, PSA ≥ 10 ng/mL, T3–T4 stage, nodal metastases, or distant metastases) and 3908 had fatal prostate cancer. Death was determined by the investigators of each contributing study using cancer registries and/or medical records. Age shows the age of diagnosis. —
[
  • 45,479 cases
  • , 26,377 controls
]
,
100.0 % Male samples
 Mean = 66.0 years
IQR = [60.0, 71.0] years		 European, NR — 60 cohorts
  • AHS
  • ,ATBC
  • ,Aarhus
  • ,BioVU
  • ,CCI
  • ,CHIPGECS
  • ,COH
  • ,CONOR
  • ,COSM
  • ,CPCS
  • ,CPDR
  • ,CeRePP
  • ,EPIC
  • ,EPICAP
  • ,ERSPC
  • ,ESTHER
  • ,FHCRC
  • ,Gene-PARE
  • ,HPFS
  • ,IMPACT
  • ,IPO-Porto
  • ,KARUPROSTATE
  • ,KULEUVEN
  • ,LAAPC
  • ,MCC-Spain
  • ,MCCS
  • ,MDACCS
  • ,MEC
  • ,MOFFITT
  • ,NMHS
  • ,PASS
  • ,PCMUS
  • ,PCPT
  • ,PCaP
  • ,PHS
  • ,PLCO
  • ,PRAGGA
  • ,PROCAP
  • ,PROFILE
  • ,PROGReSS_PrCa
  • ,PROtEuS
  • ,ProMPT
  • ,ProtecT
  • ,QLD
  • ,RAPPER
  • ,SABOR
  • ,SCCS
  • ,SCPCS
  • ,SEARCH
  • ,SELECT
  • ,SFPCS
  • ,SNP_Prostate_Ghent
  • ,SPAG
  • ,STHM
  • ,TAMPERE
  • ,Toronto
  • ,UKGPCS
  • ,ULM
  • ,WFPCS
  • ,WUGS
 —
PSS000925 Cases numbers refer to 'any prostate cancer'. Of those, 716 had aggressive prostate cancer (Gleason score ≥7, PSA ≥ 10 ng/mL, T3–T4 stage, nodal metastases, or distant metastases) and 57 had fatal prostate cancer. Death was determined by the investigators of each contributing study using cancer registries and/or medical records. Age shows the age of diagnosis. —
[
  • 1,197 cases
  • , 1,185 controls
]
,
100.0 % Male samples
 Mean = 68.0 years
IQR = [62.0, 74.0] years		 Asian unspecified, NR — 60 cohorts
  • AHS
  • ,ATBC
  • ,Aarhus
  • ,BioVU
  • ,CCI
  • ,CHIPGECS
  • ,COH
  • ,CONOR
  • ,COSM
  • ,CPCS
  • ,CPDR
  • ,CeRePP
  • ,EPIC
  • ,EPICAP
  • ,ERSPC
  • ,ESTHER
  • ,FHCRC
  • ,Gene-PARE
  • ,HPFS
  • ,IMPACT
  • ,IPO-Porto
  • ,KARUPROSTATE
  • ,KULEUVEN
  • ,LAAPC
  • ,MCC-Spain
  • ,MCCS
  • ,MDACCS
  • ,MEC
  • ,MOFFITT
  • ,NMHS
  • ,PASS
  • ,PCMUS
  • ,PCPT
  • ,PCaP
  • ,PHS
  • ,PLCO
  • ,PRAGGA
  • ,PROCAP
  • ,PROFILE
  • ,PROGReSS_PrCa
  • ,PROtEuS
  • ,ProMPT
  • ,ProtecT
  • ,QLD
  • ,RAPPER
  • ,SABOR
  • ,SCCS
  • ,SCPCS
  • ,SEARCH
  • ,SELECT
  • ,SFPCS
  • ,SNP_Prostate_Ghent
  • ,SPAG
  • ,STHM
  • ,TAMPERE
  • ,Toronto
  • ,UKGPCS
  • ,ULM
  • ,WFPCS
  • ,WUGS
 —
PSS000925 Cases numbers refer to 'any prostate cancer'. Of those, 1424 had aggressive prostate cancer (Gleason score ≥7, PSA ≥ 10 ng/mL, T3–T4 stage, nodal metastases, or distant metastases) and 18 had fatal prostate cancer. Death was determined by the investigators of each contributing study using cancer registries and/or medical records. Age shows the age of diagnosis. —
[
  • 3,240 cases
  • , 3,013 controls
]
,
100.0 % Male samples
 Mean = 62.0 years
IQR = [56.0, 68.0] years		 African unspecified, NR — 60 cohorts
  • AHS
  • ,ATBC
  • ,Aarhus
  • ,BioVU
  • ,CCI
  • ,CHIPGECS
  • ,COH
  • ,CONOR
  • ,COSM
  • ,CPCS
  • ,CPDR
  • ,CeRePP
  • ,EPIC
  • ,EPICAP
  • ,ERSPC
  • ,ESTHER
  • ,FHCRC
  • ,Gene-PARE
  • ,HPFS
  • ,IMPACT
  • ,IPO-Porto
  • ,KARUPROSTATE
  • ,KULEUVEN
  • ,LAAPC
  • ,MCC-Spain
  • ,MCCS
  • ,MDACCS
  • ,MEC
  • ,MOFFITT
  • ,NMHS
  • ,PASS
  • ,PCMUS
  • ,PCPT
  • ,PCaP
  • ,PHS
  • ,PLCO
  • ,PRAGGA
  • ,PROCAP
  • ,PROFILE
  • ,PROGReSS_PrCa
  • ,PROtEuS
  • ,ProMPT
  • ,ProtecT
  • ,QLD
  • ,RAPPER
  • ,SABOR
  • ,SCCS
  • ,SCPCS
  • ,SEARCH
  • ,SELECT
  • ,SFPCS
  • ,SNP_Prostate_Ghent
  • ,SPAG
  • ,STHM
  • ,TAMPERE
  • ,Toronto
  • ,UKGPCS
  • ,ULM
  • ,WFPCS
  • ,WUGS
 —